Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jua Choi

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Transplantation|March 19, 2019
Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney TransplantationAshley A Vo, Olivier Aubert, Mark Haas, et al.
Transplantation|January 22, 2015
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patientsAshley A Vo, Adriana Zeevi, Jua Choi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 12, 2018
A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipientsStanley C Jordan, Jua Choi, Olivier Aubert, et al.
Transplantation|May 29, 2015
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize PatientsAshley A Vo, Jua Choi, Irene Kim, et al.
Pediatric Transplantation|September 21, 2017
Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipientsIrene K Kim, Jua Choi, Ashley Vo, et al.
Transplantation|August 7, 2016
Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant RecipientsIrene K Kim, Jua Choi, Ashley A Vo, et al.
Kidney International Reports|May 2, 2022
Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney AllograftsStanley C Jordan, Noriko Ammerman, Jua Choi, et al.
Journal of Immunology Research|March 8, 2017
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant RecipientsMieko Toyoda, Bong-Ha Shin, Shili Ge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 15, 2021
Clazakizumab for desensitization in highly sensitized patients awaiting transplantationAshley A Vo, Edmund Huang, Noriko Ammerman, et al.
Clinical Transplantation|June 3, 2022
Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipientsMeghan Pearl, Patricia L Weng, Lucia Chen, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Transplantation|March 19, 2019
Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney TransplantationAshley A Vo, Olivier Aubert, Mark Haas, et al.
Transplantation|January 22, 2015
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patientsAshley A Vo, Adriana Zeevi, Jua Choi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 12, 2018
A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipientsStanley C Jordan, Jua Choi, Olivier Aubert, et al.
Transplantation|May 29, 2015
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize PatientsAshley A Vo, Jua Choi, Irene Kim, et al.
Pediatric Transplantation|September 21, 2017
Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipientsIrene K Kim, Jua Choi, Ashley Vo, et al.
Transplantation|August 7, 2016
Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant RecipientsIrene K Kim, Jua Choi, Ashley A Vo, et al.
Kidney International Reports|May 2, 2022
Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney AllograftsStanley C Jordan, Noriko Ammerman, Jua Choi, et al.
Journal of Immunology Research|March 8, 2017
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant RecipientsMieko Toyoda, Bong-Ha Shin, Shili Ge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 15, 2021
Clazakizumab for desensitization in highly sensitized patients awaiting transplantationAshley A Vo, Edmund Huang, Noriko Ammerman, et al.
Clinical Transplantation|June 3, 2022
Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipientsMeghan Pearl, Patricia L Weng, Lucia Chen, et al.
Pageof 4